Supporting Technopath Clinical Diagnostics’ accelerated growth

January 31, 2018

In January 2018, Proventus Capital Partners became Technopath Clinical Diagnostics' long-term financing partner by lending growth capital to enhance Technopath Clinical Diagnostics’ continued fast growth rate and entry into the US market.

Technopath Clinical Diagnostics is an Irish based global technology leader in the development of In Vitro Diagnostics (“IVD”) quality control solutions and software, that support the quality of patient blood testing in laboratories. Through its customers, Technopath Clinical Diagnostics supplies over 3,000 laboratories worldwide with quality control material in some 120 countries. The Company was co-founded in 2004 by CEO Malcom Bell.

Proventus Capital Partners appreciates Technopath Clinical Diagnostics’ long-term relationship with its customers and find Technopath Clinical Diagnostics to be well positioned to benefit from the underlying growth in the IVD market, driven by favourable demographic trends and the increasing importance of IVD testing in clinical decision-making in the patient treatment process.